Effect of Wf-536, a novel ROCK inhibitor, against metastasis of B16 melanoma
Tóm tắt
Rho-associated coiled-coil-forming protein kinase (ROCK) is pivotally involved in invasion by tumor cells and their evolution to metastasis. We have developed a novel inhibitor of ROCK, Wf-536 [(+)-(R)-4-(1-aminoethyl)-N-(4-pyridyl) benzamide monohydrochloride]. In the present study, we investigated its effect on in vitro invasion and in vivo pulmonary metastasis of B16 melanoma. The following were evaluated: the anti-invasive effect of Wf-536 against the motility of mouse B16BL6 melanoma cells through a culture insert layered with reconstituted basement membrane (Matrigel); the cytotoxic effect of Wf-536 in the same cell line; the antimetastatic effect of Wf-536, administered by osmotic pump, on spontaneous pulmonary metastasis following subcutaneous injection of B16BL6 melanoma in mice; and the inhibitory effect of orally administered Wf-536, alone or in combination with the antineoplastic drug paclitaxel, on pulmonary metastasis of intravenously injected B16F10 melanoma in mice. Wf-536 inhibited in vitro invasion by B16BL6 cells significantly and in a concentration-dependent manner and displayed an anti-invasive effect under conditions of both chemotaxis and chemokinesis. No cytotoxic effect was observed at any of the concentrations used. In vivo, Wf-536 administration suppressed tumor colony formation on the lung surface in a dose-dependent manner (0.3–3 mg/kg per day), with a metastasis inhibition rate of 95% at 3 mg/kg per day. In experimental metastasis of B16F10 melanoma, oral administration of Wf-536 significantly decreased tumor colony formation in the lung, with an inhibition rate of 41% at 3 mg/kg per day. The inhibition rate of paclitaxel (5 mg/kg per day) was 27%. The combination of Wf-536 and paclitaxel produced a synergistic effect on B16F10 metastasis and a 68% inhibition rate. Wf-536 administration at the doses used did not alter body weight, blood pressure or the health of treated animals as compared to vehicle-treated controls. The results suggest that Wf-536 is a potentially valuable drug for preventing tumor metastasis both in monotherapy and in combination with an antineoplastic drug.
Tài liệu tham khảo
Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, Giavazzi R, Taraboletti G (1996) The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2:1843
Blagosklonny MV, Chuman Y, Bergan RC, Fojo T (1999) Mitogen-activated protein kinase pathway is dispensable for microtubule-active drug-induced Raf-1/Bcl-2 phosphorylation and apoptosis in leukemia cells. Leukemia 13:1028
Chirivi RG, Garofalo A, Crimmin MJ, Bawden LJ, Stoppacciaro A, Brown PD, Giavazzi R (1994) Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 58:460
Ferrante K, Winograd B, Canetta R (1999) Promising new developments in cancer chemotherapy. Cancer Chemother Pharmacol [Suppl] 43:S61
Fidler IJ (1975) Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res 35:218
Fujii A, Otsuki M, Kataoka H, Chiba K, Fujita F, Koike M, Fujita M, Sakamoto Y (2001) Wf-536, a novel and potent inhibitor of Rho-associated protein kinase (ROCK): inhibitory effects on lymph node and pulmonary metastasis of mouse B16-F10 melanoma. Proc Am Assoc Cancer Res 42:924
Haldar S, Basu A, Croce CM (1997) Bcl-2 is the guardian of microtubule integrity. Cancer Res 57:229
Hart IR (1979) The selection and characterization of an invasive variant of the BL6 melanoma. Am J Pathol 97:587
Hayashi K, Amano Y, Katayama K, Nakajima M, Egi Y, Uehata M, Arii S, Imamura M, Goto N (2001) Wf-536, a novel and potent inhibitor of Rho-associated protein kinase (ROCK): inhibition of in vitro tumor cell invasion and spontaneous evolution of mouse tumors into metastasis. Proc Am Assoc Cancer Res 42:924
Imamura F, Mukai M, Ayaki M, Akedo H (2000) Y-27632, an inhibitor of Rho-associated protein kinase, suppresses tumor cell invasion via regulation of focal adhesion and focal adhesion kinase. Jpn J Cancer Res 91:811
Inoue K, Slaton JW, Perrotte P, Davis DW, Bruns CJ, Hicklin DJ, McConkey DJ, Sweeney P, Radinsky R, Dinney CP (2000) Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 6:4874
Itoh K, Yoshioka K, Akedo H, Uehata M, Ishizaki T, Narumiya S (1999) An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat Med 5:221
Kahan BD (1995) Concentration-controlled immunosuppressive regimens using cyclosporine with sirolimus or brequinar in human renal transplantation. Transplant Proc 27:33
Kalechman Y, Longo DL, Catane R, Shani A, Albeck M, Sredni B (2000) Synergistic anti-tumoral effect of paclitaxel (Taxol)+AS101 in a murine model of B16 melanoma: association with ras-dependent signal-transduction pathways. Int J Cancer 86:281
Ling V, Chambers AF, Harris JF, Hill RP (1985) Quantitative genetic analysis of tumor progression. Cancer Metastasis Rev 4:173
Locker J, Goldblatt PJ, Leighton J (1970) Ultrastructural features of invasion in chick embryo liver metastasis of Yoshida ascites hepatoma. Cancer Res 30:1632
Miller KD, Sweeney CJ, Sledge GW Jr (2001) Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 19:1195
Mohler JL, Partin AW, Coffey DS (1987) Prediction of metastatic potential by a new grading system of cell motility: validation in the Dunning R-3327 prostatic adenocarcinoma model. J Urol 138:168
Nakajima M, Katayama K, Tamechika I, Hayashi K, Amano Y, Uehata M, Goto N (2001) Wf-536, a novel and potent inhibitor of Rho-associated protein kinase (ROCK): inhibition of in vitro processes leading to tumor cell invasion and vascularization. Proc Am Assoc Cancer Res 42:924
Neri A, Goggin B, Kolis S, Brekken J, Khelemskaya N, Gabriel L, Robinson SR, Webber S, Wood AW, Appelt K, Shalinsky DR (1998) Pharmacokinetics and efficacy of a novel matrix metalloproteinase inhibitor, AG3340, in single agent and combination therapy against B16-F10 melanoma tumors developing in lung after IV-tail implantation in C57BL/6 mice. Proc Am Assoc Cancer Res 39:2060
Partin AW, Mohler JL, Coffey DS (1992) Cell motility as an index of metastatic ability in prostate cancers: results with an animal model and with human cancer cells. Cancer Treat Res 59:121
Rowinski EK (1994) Update on the antitumor activity of paclitaxel in clinical trials. Ann Pharmacother 28: S18
Schiff PB, Horwitz SB (1980) Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A 77:1561
Shalinsky DR, Brekken J, Zou H, Mcdermott CD, Forsyth P, Edwards D, Margosiak S, Bender S, Truitt G, Wood A, Varki NM, Appelt K (1999) Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. In: Greenwald RA, Zucker S, Golub LM (ed) Inhibition of matrix metalloproteinases: therapeutic applications. Ann N Y Acad Sci 878:236
Somlyo AV, Bradshaw D, Ramos S, Murphy C, Myers CE, Somlyo AP (2000) Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. Biochem Biophys Res Commun 269:652
Watanabe K, Ito S, Kikuchi K, Ichikawa N, Ando Y, Meigata K, Nomura Y, Degata T, Beck Y, Tomikawa S, Nagao T, Uchida H (1996) Synergistic effect of tacrolimus and mizoribine on in vitro and in vivo experiments assessed by a combination index. Jap J Transplant 31:23
Wyckoff JB, Jones JG, Condeelis JS, Segall JE (2000) A critical step in metastasis: in vivo analysis of intravasation at the primary tumor. Cancer Res 60:2504
Zagozdzon R, Golab J, Mucha K, Foroncewicz B, Jakobisiak M (1999) Potentiation of antitumor effects of IL-12 in combination with paclitaxel in murine melanoma model in vivo. Int J Mol Med 4:645